Is Edema Zone Volume Associated With Ki-67 Index in Glioblastoma Patients?

Introduction Despite all the progress with genetic mapping and multimodal treatment, the prognosis of Glioblastoma multiforme (GBM) remains poor, with median overall survival (OS) of only 12 to 15 months. Several studies showed correlations between glioblastoma clinic and prognosis factors; however, it doesn`t occur with tumor radiological features. The purpose of this study is to determine possible correlations between the volumetric analysis of glioblastoma compartments and the proliferation index represented by Ki-67. Methods We performed a retrospective analysis of MRI studies of 70 patients with glioblastoma multiforme acquired up to one week before surgery. The tumor compartments were divided into enhancing zone; edema zone and tumor total zone. Each compartment was submitted to volumetric analysis using Horos Project software. A linear regression model was used to assess correlations between the ki-67 index and the volume of each compartment with a p-value of 0.05. Results The male/female ratio in our study was 1.7:1, at a mean age of 60.7 ± 14.6 years. Tumor predominant location was the temporal lobe with 25% of cases and cystic morphology was present in 17%. The median of Ki-67 was 40%. The average tumor compartment volume was 40 cm3 for the contrast-enhancing zone, 62 cm3for the edema zone, and 103 cm3 for the total tumor volume. A significant association between the Ki-67 index and edema zone volume (p=0.02) was found. Conclusion Volumetric analysis of the glioblastoma edema zone by MRI allows for predicting tumor aggressiveness through correlation with the Ki-67 index.

[1]  P. Lambin,et al.  Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma , 2021, Cancers.

[2]  A. Frati,et al.  Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation , 2020, Clinical Neurology and Neurosurgery.

[3]  Jia Fu,et al.  Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas , 2020, BMC Cancer.

[4]  Leland S. Hu,et al.  Assessment of Prognostic Value of Cystic Features in Glioblastoma Relative to Sex and Treatment With Standard-of-Care , 2019, Frontiers in Oncology.

[5]  A. Erbersdobler,et al.  Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma. , 2019, World neurosurgery.

[6]  V. Gebski,et al.  Cut‐point for Ki‐67 proliferation index as a prognostic marker for glioblastoma , 2019, Asia-Pacific journal of clinical oncology.

[7]  M. Korja,et al.  Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland , 2018, Neuro-oncology.

[8]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.

[9]  Mohammed A. Alharbi,et al.  Ki-67 labeling index in glioblastoma; does it really matter? , 2019, Hematology/oncology and stem cell therapy.

[10]  Tomasz Tykocki,et al.  Ten-year survival in glioblastoma. A systematic review , 2018, Journal of Clinical Neuroscience.

[11]  M. Paknahad,et al.  Cancers of the Brain and CNS: Global Patterns and Trends in Incidence , 2018, Journal of biomedical physics & engineering.

[12]  J. Piek,et al.  Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival , 2017, Journal of Neuro-Oncology.

[13]  F. Bray,et al.  Cancers of the brain and CNS: global patterns and trends in incidence , 2016, Neuro-oncology.

[14]  Dima Suki,et al.  Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[15]  Anthony A. Hyman,et al.  Ki-67 acts as a biological surfactant to disperse mitotic chromosomes , 2016, Nature.

[16]  K. Fürst,et al.  Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme , 2016, Journal of Neuro-Oncology.

[17]  Atle Bjørnerud,et al.  Volumetric glioma quantification: comparison of manual and semi-automatic tumor segmentation for the quantification of tumor growth , 2015, Acta radiologica.

[18]  F. Ren,et al.  Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[19]  Andrejs Vanags,et al.  Heterogeneity of Ki-67 and p53 Expression in Glioblastoma , 2014 .

[20]  Y. Dang,et al.  Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[21]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[22]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[23]  Bruce Shadbolt,et al.  A multicenter study of primary brain tumor incidence in Australia (2000-2008). , 2011, Neuro-oncology.

[24]  H. Mehdorn,et al.  Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. , 2010, European journal of cancer care.

[25]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[26]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[27]  H. Shimizu,et al.  Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. , 2000, AJNR. American journal of neuroradiology.